CD80 and ovarian serous adenocarcinoma: Using the CD28-CD80 (B7-1) family as a positive control, we show that this method can identify canonical co-stimulatory signaling in the Cancer Genome Atlas (TCGA) study of high-grade serous ovarian cancers [15].